pipette
ENEnglish

Cytotoxic drugs and bispecific T cell engagers synergize to rewire host immunity and elicit polyclonal antitumor T cell responses

Dylan Kwart, Qiaozhi Wei, Wei‐Yi Cheng, Kamilah Ryan, Allen Y. Leary, Jacquelynn Golubov, Ciara Torres, Patrick Poon, Jacqueline J. Warsaw, Jacob Lowy, Erica Ullman, Aynur Hermann, Jennifer Finney, Lauric Haber, Albert Canturri, Dharani K. Ajithdoss, Andria Skinner, Eric Smith, Christopher Daly, Jeremy S. Rabinowitz, Erin Paul, Nicole Stokes Oristian, William T. Poueymirou, Christina Adler, Min Ni, Namita T. Gupta, Frank A. Seebach, Melissa Divya Mathias, Matthew Fury, Israel Lowy, William Olson, John C. Lin, Andrew J. Murphy, Bei Wang, Dimitris Skokos

Revista con revisión por paresAfirmaciones fuertes, leer con cuidadoUso en el mundo real

En palabras de los autores

Cytotoxic therapies such as chemotherapy and antibody-drug conjugates (ADCs) kill tumor cells directly but are limited by resistance, dose-limiting toxicity, and failure to induce durable antitumor immunity. Here we show that tumor-associated antigen (TAA)-targeted CD28 bispecific antibodies (TAAxCD28) convert cytotoxic agents into drivers of durable antitumor immunity. In humanized mouse models, combining the HER2-directed ADC trastuzumab deruxtecan (Tras-DXd) with TAAxCD28 antibodies enhances tumor rejection and promotes durable immune memory in Tras-DXd-resistant cancers, and comparable synergy is observed with 5-fluorouracil (5-FU). This therapeutic strategy allows lower or less frequent cytotoxic drug dosing, potentially limiting systemic toxicity. Mechanistically, TAAxCD28 antibodies promote the activation and expansion of clonally-restricted tumor CD8+ T cells, and adding ADCs or chemotherapy sustains this activation while preserving a naïve/stem-like pool of tumor-specific CD8+ T cells with a diversified T cell receptor repertoire. Each cytotoxic agent supports this T cell activity through a separate innate mechanism: Tras-DXd expands and activates conventional dendritic cells, whereas 5-FU reprograms suppressive myeloid cells toward an immunostimulatory phenotype. Together, these findings support pairing cytotoxic agents with TAAxCD28 bispecifics to overcome resistance and improve long-term tumor control in refractory cancers. TAA×CD28 costimulatory bispecific antibodies are a class of immunotherapeutics that provide tumor-targeted CD28 costimulation to T cells by crosslinking CD28 on T cells to a tumor-associated antigen (TAA) expressed on tumor cells. Here, the authors show that cytotoxic therapies reprogram the tumor microenvironment and augment the antitumor immunity induced by TAA×CD28 bispecifics.

Resultado principalEl resumen no menciona limitaciones.

Apareció: martes, 17 de noviembre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-79192-3